MW AstraZeneca to become latest drugmaker to strike deal with Trump. Its stock is down but outperforming the market.

By Victor Reklaitis

British company looks set to follow in Pfizer's footsteps

AstraZenenca looks set for a deal with President Trump. The company sponsored the #66 car at Nascar's Coca-Cola 600 at Charlotte Motor Speedway in May.

AstraZeneca PLC looks poised to announce a deal with U.S. President Donald Trump that's focused on lowering drug prices, in a move that would see the British drugmaker follow in the footsteps of Pfizer Inc.

Last week, Pfizer $(PFE)$ and Trump rolled out an agreement in which the American company will avoid tariffs for three years in exchange for charging reduced prices on some of its drugs and participating in the White House's new direct-to-consumer website, TrumpRx.gov.

The agreement between Pfizer and Trump has been viewed as providing a framework for other drugmakers aiming to make a deal with the Trump administration.

Multiple published reports said the agreement between AstraZenenca and Trump would be announced later Friday, but details weren't yet clear. The White House didn't immediately respond to MarketWatch's request for comment. Trump's schedule said he would make an announcement at 5 p.m. Eastern time.

AstraZeneca's U.S.-listed shares $(AZN)$ were down by 0.9% in recent trading Friday - but were performing better than the broader stock market, which was getting hit by a new Trump threat to impose higher tariffs on China. The S&P 500 stock index SPX was lower by more than 2%, while drugmakers overall, as tracked by the VanEck Pharmaceutical ETF PPH, were off by 1.5%.

.

-Victor Reklaitis

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

October 10, 2025 15:45 ET (19:45 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.